“With Third Rock Ventures, my interactions are not limited to an assigned partner at the fund; rather, I have access to everyone at Third Rock and can tap their respective expertise and insights as needed. This has been a tremendous asset to me as a first time CEO.”
– David Schenkein, M.D., Chief Executive Officer, Agios Pharmaceuticals
While we have $378 million in managed funds to invest in our portfolio companies, we think our partnerships are priceless. That’s because with every partnership, we invest our time, talent, leadership, operational expertise and R&D insight that you can’t get in a short monthly board meeting. We are company builders and focus on working closely with the scientific and business community to identify disruptive science and technology that will shape the future of medicine.
When we get involved in the formative stages of company, we consider investments based on the following criteria:
We invest for success…
Our strategy is to lead investing rounds in uniquely innovative life sciences businesses, making an initial investment of up to $35 million, ideally at the formative stage of company development.
…with extraordinary scientists and entrepreneurs…
We seek to work with great founders who possess inspiration, insight, and tenacity.
…who have transformational ideas…
We seek opportunities to build companies around breakthrough innovations and “product engines” - new platforms capable of creating multiple products for different diseases. We also consider other outstanding product opportunity investments. We engage early in our investment process with large life sciences companies, exploring novel, mutually beneficial partnerships to launch successful biotech and medtech companies together.
… to which we can add value.
We pursue opportunities where we can add value through our unique collaborative approach to launch companies, and provide scientific or business expertise as well as capital to help accelerate their growth.
